Captopril and dihydralazine both prevented genetic hypertension development in spontaneously hypertensive rats, reducing mean blood pressure to 117 mmHg compared to 160 mmHg in controls.
Does captopril or dihydralazine prevent functional and morphological vascular alterations during genetic hypertension development in spontaneously hypertensive rats?
Captopril, unlike dihydralazine, exerts long-lasting protective effects on vascular structure and function in spontaneously hypertensive rats even after treatment is stopped.
Absolute Event Rate: 117% vs 160%
p-value: p=<0.001
When administered to young spontaneously hypertensive rats (SHRs), dihydralazine (25 mg kg-1, daily) and captopril (100 mg kg-1, daily) prevent with the same efficacy genetic hypertension development (GHD). Dihydralazine treatment increased vascular mesenteric compliance, as shown by a significant decrease in the stiffness of the vessels (-27%), and induced slight reductions in contractility (-12%) and in wall to lumen (W/L) ratio (-15%). After treatment withdrawal, all these parameters returned to control values within 7 weeks, as did blood pressure. Captopril treatment also strongly increased the mesenteric vessels compliance, vessel stiffness being decreased by 16%, and reduced their contractility (-15%) and their W/L ratio (-30%). These effects as well as those exerted on blood pressure persisted up to 7 weeks after treatment ceased although there was a slight trend to a progressive reduction in the intensity of both phenomena. These experiments show that captopril but not dihydralazine has a long-lasting effect in opposing the functional and morphological vascular alterations occurring during GHD in SHRs and this phenomenon probably contributes to a large extent to the sustained preventive effects of the drug against GHD.
Freslon et al. (Tue,) conducted a other in Genetic hypertension development (n=120). Captopril and Dihydralazine vs. Distilled water was evaluated on Mean blood pressure (MBP) at 20 weeks of age (p=<0.001). Captopril and dihydralazine both prevented genetic hypertension development in spontaneously hypertensive rats, reducing mean blood pressure to 117 mmHg compared to 160 mmHg in controls.